4- (3- (2H- 1,2,3- triazol- 2- yl)phenylamino)- 2- (2- aminocyclohexylamino)pyrimidine- 5- carboxamide

a spleen tyrosine kinase (Syk) inhibitor; structure in first source

Also Known As:

P505-15; PRT062607

Networked: 9 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Amines: 4871
  - Cyclohexylamines: 33
    - 4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-(2-aminocyclohexylamino)pyrimidine-5-carboxamide: 9
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Cyclohexanes: 3
        Cyclohexylamines: 33
        4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-(2-aminocyclohexylamino)pyrimidine-5-carboxamide: 9
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - 4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-(2-aminocyclohexylamino)pyrimidine-5-carboxamide: 9

Experts

1.	Betz, Andreas: 3 articles (01/2017 - 02/2013)
2.	Coffey, Greg: 3 articles (01/2017 - 02/2013)
3.	Sinha, Uma: 3 articles (01/2017 - 02/2013)
4.	Pak, Yvonne: 2 articles (01/2017 - 02/2013)
5.	Pandey, Anjali: 2 articles (01/2017 - 02/2013)
6.	Ding, Changhai: 1 article (03/2022)
7.	Tang, Su'an: 1 article (03/2022)
8.	Yu, Qinghong: 1 article (03/2022)
9.	Cong, Wei: 1 article (01/2021)
10.	Feng, Haotian: 1 article (01/2021)

Related Diseases

1.	Neoplasms (Cancer) 07/01/2012 - "These findings demonstrate that the selective Syk inhibitors PRT318 and P505-15 are highly effective for inhibition of CLL survival and tissue homing circuits, and support the therapeutic development of these agents in patients with CLL, other B-cell malignancies and autoimmune disorders." 02/01/2013 - "Our findings support the ongoing development of P505-15 as a therapeutic agent for B-cell malignancies. "
2.	Rheumatoid Arthritis 12/01/2013 - "PRT062607 (P505-15) is a highly selective small molecule Syk inhibitor that potently suppresses B-cell function in human and rodent blood, and reduces inflammation in rodent models of rheumatoid arthritis (RA). " 08/01/2015 - "Therefore, the present study examined the effect of SYK inhibition with the selective spleen tyrosine kinase inhibitor P505-15 in experimental rheumatoid arthritis (RA) using a murine model of collagen-induced arthritis (CIA). "
3.	Experimental Arthritis 01/01/2017 - "Clinical PK/PD was related to in vivo anti-inflammatory activity of PRT062607 in the rat collagen-induced arthritis model, which predicts that therapeutic concentrations may be safely achieved in humans for the treatment of autoimmune disease. " 08/01/2015 - "Therefore, the present study examined the effect of SYK inhibition with the selective spleen tyrosine kinase inhibitor P505-15 in experimental rheumatoid arthritis (RA) using a murine model of collagen-induced arthritis (CIA). "
4.	Inflammation (Inflammations) 12/01/2013 - "PRT062607 (P505-15) is a highly selective small molecule Syk inhibitor that potently suppresses B-cell function in human and rodent blood, and reduces inflammation in rodent models of rheumatoid arthritis (RA). " 12/01/2013 - "Disease severity, serum protein markers of inflammation, and co-medications were related to each other, and to PRT062607 activity in ex vivo Syk-mediated immune function assays. " 01/01/2019 - "We found that inhibition of SYK with the selective small molecule inhibitors Piceatannol and PRT062607 markedly protected against toxin-induced hepatic fibrosis, associated hepatocellular injury and intra-hepatic inflammation, and hepatocarcinogenesis. "
5.	Autoimmune Diseases (Autoimmune Disease) 01/01/2017 - "Clinical PK/PD was related to in vivo anti-inflammatory activity of PRT062607 in the rat collagen-induced arthritis model, which predicts that therapeutic concentrations may be safely achieved in humans for the treatment of autoimmune disease. " 03/01/2022 - "The search terms used were SYK inhibitors, R406, fostamatinib (R788), P505-15 (PRT062607), entospletinib (GS-9973), R112, lanraplenib (GS-9876), cerdulatinib, R343, BAY-61-3606, GSK compound 143 (GSK143), R211, SKI-G-618, SKI-O-85, ER-27319, YM193306, RO9021 in conjunction with autoimmune disease using electronic databases including PubMed, EMBASE, MEDLINE and Google Scholar. "

Related Drugs and Biologics

1.	Syk Kinase
2.	4- (3- (2H- 1,2,3- triazol- 2- yl)phenylamino)- 2- (2- aminocyclohexylamino)pyrimidine- 5- carboxamide
3.	fostamatinib
4.	Phosphotransferases (Kinase)
5.	Blood Proteins (Serum Proteins)
6.	GSK143
7.	2- (7- (3,4- dimethoxyphenyl)imidazo(1,2- c)pyrimidin- 5- ylamino)nicotinamide
8.	ER 27319
9.	3,3',4,5'-tetrahydroxystilbene
10.	fludarabine

Related Therapies and Procedures

1.	Ovariectomy (Oophorectomy)